高迁移率族蛋白盒3基因rs3803662与乳腺癌风险：一项荟萃分析。

TOX high mobility group box family member 3 rs3803662 and breast cancer risk: A meta-analysis.

作者信息

Li Lin, Guo Guangcheng, Wang Fang, Lv Pengwei, Zhu Mingzhi, Gu Yuanting, Han Mingli, Pei Xinhong

机构信息

Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.

出版信息

J Cancer Res Ther. 2018;14(Supplement):S208-S212. doi: 10.4103/0973-1482.167611.

DOI:10.4103/0973-1482.167611

PMID:29578175

Abstract

AIMS

Some studies suggested that TOX high mobility group box family member 3 (TOX3) rs3803662 polymorphism was associated with the risk of breast cancer. However, the results were controversy. Therefore, in order to derive a more comprehensive estimation of the association between TOX3 rs3803662 polymorphism and breast cancer risk, we conducted a meta-analysis to investigate this relationship.

MATERIALS AND METHODS

An electronic literature search was conducted using the following database: PubMed, EMBASE, and China National Knowledge Infrastructure till to March 31, 2015. The strength of the associations between the TOX3 rs3803662 polymorphism and breast cancer risk in per alle model was measured by odds ratios (ORs) and 95% confidence intervals (CIs).

RESULTS

A statistically significant association between TOX3 rs3803662 polymorphism and breast cancer risk was fond. The data showed that TOX3 rs3803662 polymorphism could increase the risk of breast cancer (OR = 1.20; 95% CI: 1.16-1.25; P < 0.00001). In the subgroup analysis of race, Caucasians, Asians, and Hispanics also showed increased breast cancer risk (OR = 1.21; 95% CI: 1.17-1.25; P < 0.00001; OR = 1.20; 95% CI: 1.08-1.33; P = 0.0004; OR = 1.32; 95% CI: 1.12-1.57; P = 0.001). However, African-Americans with TOX3 rs3803662 polymorphism showed decreased breast cancer risk (OR = 0.95; 95% CI: 0.86-1.04; P = 0.28), although the result was not significant. When considered estrogen receptor (ER) status, we found that ER subjects and ER subjects all had increased breast cancer risk, if they carried this polymorphism (OR = 1.27; 95% CI: 1.19-1.35; P < 0.00001; OR = 1.12; 95%CI: 1.08-1.17; P < 0.00001). Similarly, both progesterone receptor-positive (PR ) subjects and PR subjects all showed increased breast cancer risk, if they carried this polymorphism (OR = 1.32; 95% CI: 1.17-1.49; P < 0.00001; OR = 1.15; 95% CI: 1.09-1.23; P < 0.00001).

CONCLUSIONS

This meta-analysis suggested that TOX3 rs3803662 polymorphism was associated with increased breast cancer risk.

摘要

目的

一些研究表明，高迁移率族蛋白盒3（TOX3）基因rs3803662多态性与乳腺癌风险相关。然而，结果存在争议。因此，为了更全面地评估TOX3基因rs3803662多态性与乳腺癌风险之间的关联，我们进行了一项荟萃分析来研究这种关系。

材料与方法

使用以下数据库进行电子文献检索：PubMed、EMBASE和中国知网，检索截至2015年3月31日的文献。在等位基因模型中，通过比值比（OR）和95%置信区间（CI）来衡量TOX3基因rs3803662多态性与乳腺癌风险之间关联的强度。

结果

发现TOX3基因rs3803662多态性与乳腺癌风险之间存在统计学显著关联。数据显示，TOX3基因rs3803662多态性可增加乳腺癌风险（OR = 1.20；95%CI：1.16 - 1.25；P < 0.00001）。在种族亚组分析中，高加索人、亚洲人和西班牙裔也显示出乳腺癌风险增加（OR = 1.21；95%CI：1.17 - 1.25；P < 0.00001；OR = 1.20；95%CI：1.08 - 1.33；P = 0.0004；OR = 1.32；95%CI：1.12 - 1.57；P = 0.001）。然而，携带TOX3基因rs3803662多态性的非裔美国人显示出乳腺癌风险降低（OR = 0.95；95%CI：0.86 - 1.04；P = 0.28），尽管结果不显著。在考虑雌激素受体（ER）状态时，我们发现，如果携带这种多态性，ER阳性和ER阴性受试者的乳腺癌风险均增加（OR = 1.27；95%CI：1.19 - 1.35；P < 0.00001；OR = 1.ll；%CI：1.08 - 1.17；P < 0.00001）。同样，携带这种多态性的孕激素受体阳性（PR +）和PR阴性受试者的乳腺癌风险均增加（OR = 1.32；95%CI：1.17 - 1.49；P < 0.00001；OR = 1.15；95%CI：1.09 - 1.23；P < 0.00001）。